A Clinical Trial of Investigational Medicinal Product (CTIMP) is a clinical trial or study that is evaluating the safety or efficacy of a drug (Investigational Medicinal Product) or obtaining any other information about the drug e.g. how it is absorbed, distributed, metabolised or excreted. This is because they involve administering medicinal products to patients so they are higher risk and require stricter regulations than other types of trial. The 24/7 delivery team at University Hospitals Birmingham that works within trauma, burns and critical care (and is partially supported by the NIHR SRMRC) is currently running four CTIMPs.
At the end of each financial year, UHB publishes a list of the top 10 Principal Investigators (PIs) and the number of patients they have recruited to these challenging trials. Trial PIs are the individuals responsible for the conduct of the research at a research site. Last year, three of the PIs who work within our delivery team made it onto this list:
Dr Dhruv Parekh (Consultant in Critical Care and Respiratory Medicine) for the Covid REMAP-CAP trial.
Dr Jaimin Patel (Consultant in Intensive Care Medicine and Anaesthesia) for the VitDalize trial.
Col Mark Foster (Consultant in Hand and Plastic Surgery) for the ADaPT trial, which is an NIHR SRMRC core-funded study.
Of course, none of this could have been achieved without the support of the rest of the delivery team and the patients and families who kindly agree to their participation.